March 22, 2024Cancer Research

Prostate Cancer Patient-Derived Xenograft and Cellular Platform for Drug Screening

View Full Paper

Ask AI

Bookmark

Authors

ÉIÉmilie IndersieCentre National de la Recherche Scientifique LSLéa SinayenUniversité d'Évry Val-d'Essonne LBLudovic BigotInserm

Discussion

Member takes

Implication

Preclinical evaluation demonstrates diverse pharmacological responses across patient-derived prostate cancer models, highlighting new platforms for overcoming therapy resistance.

Key Points

Patient-derived xenografts faithfully reproduce the molecular heterogeneity and clinical drug responses of prostate tumors, providing robust translational models for oncology.
The platform contains 11 patient-derived xenografts and 6 matching cell models, which whole exome sequencing confirmed retain parental genomic alterations across disease subtypes.
Transplantation of tumor fragments and circulating tumor cells into mice established lines sensitive to enzalutamide; mouse model, further preclinical validation is required.

Cite This Study

Indersie et al. (2024) studied this question.

synapsesocial.com/papers/68e72e1db6db6435876a7269 https://doi.org/10.1158/1538-7445.am2024-6913

View Full Paper

Ask AI

Bookmark

Implication

Preclinical evaluation demonstrates diverse pharmacological responses across patient-derived prostate cancer models, highlighting new platforms for overcoming therapy resistance.

Prostate Cancer Patient-Derived Xenograft and Cellular Platform for Drug Screening

Discussion

Member takes

Implication

Key Points

Cite This Study

Prostate Cancer Patient-Derived Xenograft and Cellular Platform for Drug Screening

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider